Johnson & Johnson vs. Spyre Therapeutics, Inc. Common Stock
Johnson & Johnson and Spyre Therapeutics, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| JNJ | SYRE | |
|---|---|---|
| Market Cap | $650.67 billion | $8.25 billion |
| Revenue (TTM) | $97.93 billion | — |
| Net Income (TTM) | $21.04 billion | — |
JNJ leads on 1 of 1 size & scale factors.
Valuation
| JNJ | SYRE | |
|---|---|---|
| P/E Ratio | 31.32 | — |
| Price / Book | 7.66 | — |
| Price / Sales | 6.64 | — |
JNJ and SYRE split the valuation factors evenly.
Profitability
| JNJ | SYRE | |
|---|---|---|
| Net Margin | 21.48% | — |
| Return on Equity | 24.76% | — |
JNJ and SYRE split the profitability factors evenly.
Dividend
| JNJ | SYRE | |
|---|---|---|
| Dividend Yield | 1.99% | — |
| Payout Ratio | 62.18 | — |
JNJ and SYRE split the dividend factors evenly.
Risk & Sentiment
| JNJ | SYRE | |
|---|---|---|
| Short Interest | 0.67% | 0.23% |
SYRE leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, SYRE overview, SYRE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.